Skip to content

Eupraxia Pharmaceuticals

US · EPRX #3732 by market cap
5.80 -0.32 -5.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 6.08 -0.65%
After-hours 5.80 0.00%
9.105.805.802026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on EPRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -10.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 9.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -142.9% Better than 4%
Return on invested capital -147.3% Better than 1%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -13.8% Better than 42%
6-month return -18.3% Better than 29%
12-month return (ex latest month) 10.6% Better than 47%
Distance below 52-week high 37.8% Better than 31%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.1x Better than 96%
Debt to assets 0.2% Better than 98%
Interest coverage -41.7x Better than 8%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 197.4% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -28.83%
1M -23.58%
3M -14.20%
6M -8.95%
YTD -23.18%
1Y -6.60%

Key statistics

Price & volume

Prev close
6.12
Open
6.11
Day range
5.69 - 6.42
Avg price
5.84
Volume
361.67K
Turnover
2.11M
Amplitude
11.93%
52-week range
5.63 - 9.32

Valuation

P/E
-5.63
P/E (TTM)
-5.42
P/B
4.26
EPS
-1.03
Net profit
-69.29M
Net assets
91.55M

Share structure

Market cap
390.16M
Float cap
330.78M
Shares out
67.27M
Float shares
57.03M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 5% of range
5.63 9.32

37.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+3.18M net over the window

Short interest

Shares short
6.25M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Eupraxia Pharmaceuticals (EPRX)?

Eupraxia Pharmaceuticals last traded at 5.80. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Eupraxia Pharmaceuticals's market cap?

About 390.16M.

What is the P/E ratio of Eupraxia Pharmaceuticals?

The trailing twelve-month P/E is -5.42. The Valuation tab shows it against the stock's own five-year range.

Does Eupraxia Pharmaceuticals pay a dividend?

Eupraxia Pharmaceuticals does not currently pay a regular dividend.

Is Eupraxia Pharmaceuticals a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 17.25, which implies 197.4% upside from the current price. This is not investment advice.

What is Eupraxia Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Eupraxia Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Eupraxia Pharmaceuticals discussion 0 comments

Add a comment